Katherine A. High - Form 4 Filing

This Form 4 filing details a stock option grant to Katherine A. High, a director at CRISPR Therapeutics AG. The option, for 13,000 shares of Common Shares, was granted on June 5, 2026, with a $0.00 transaction price per share. The option is exercisable at $51.84 per share and will vest in 12 equal monthly installments starting June 30, 2026, with full vesting by June 5, 2027, or the 2027 Annual Meeting. Ms. High holds these options directly, and post-transaction, she owns 13,000 shares underlying this option. The filing was signed on June 9, 2026.